Given the lack of anti-tumor efficacy and in the case of LFA-1 blockers, the severity of adverse events, it could be more feasible to target the integrin ligands on tumor vessels than the integrins themselves in order to enhance T cell infiltration to the tumor site. Here, ITGB2 is linked to neoplasm.